Dislipidemili Hastada Tanı ve Tedavi Yaklaşımları
Özet
Dislipidemi, kolesterol ve lipoprotein metabolizmasındaki bozukluklar sonucu gelişen ve ateroskleroz yoluyla kardiyovasküler hastalık riskini artıran en önemli faktörlerdendir. Tanı aşamasında 20 yaş üzerindeki bireylerin 5 yılda bir lipid paneli ile taranması, aile öyküsünün incelenmesi ve hipotiroidi, diyabet veya böbrek hastalıkları gibi sekonder nedenlerin dışlanması kritik bir önem taşır. Tedavi yaklaşımı ise tamamen hastanın taşıdığı kardiyovasküler risk derecesine göre şekillendirilir; bu doğrultuda yüksek riskli hastalarda LDL kolesterol seviyesinin agresif bir şekilde 70 mg/dl'nin altına indirilmesi hedeflenir. İlk basamakta diyet, düzenli egzersiz ve alkol kısıtlaması gibi non-farmakolojik yaşam tarzı değişiklikleri uygulanır. Ancak bu yöntemlerin tek başına yetersiz kaldığı durumlarda ya da genetik geçişli primer dislipidemi tablolarında farmakolojik tedaviye başvurulur. Klinik pratikte lipid düşürücü ajanlar arasında HMG-CoA redüktaz enzimini inhibe eden statinler ilk tercih olarak öne çıkarken; hastanın ihtiyacına göre ezetimib, fibratlar, nikotinik asit ve omega-3 yağ asitleri gibi diğer medikal seçenekler de tedavi protokolüne dahil edilir.
Dyslipidemia arises from disorders in cholesterol and lipoprotein metabolism, serving as a primary risk factor that promotes atherosclerosis and elevates cardiovascular diseases. Diagnostic strategies recommend a comprehensive fasting lipid panel screening every five years for individuals over 20, alongside thorough physical examinations and secondary cause evaluations like hypothyroidism, diabetes, or renal pathologies. Therapeutic management is entirely tailored to the patient's individual cardiovascular risk profile, aiming for aggressive LDL reduction below 70 mg/dl in very high-risk populations. Management initiates with essential non-pharmacological interventions, including dietary adjustments, consistent exercise, and smoking or alcohol cessation. When lifestyle modifications prove insufficient or in cases of severe genetic lipoprotein disorders, pharmacological therapies are promptly implemented. Statins represent the frontline medication class by inhibiting the HMG-CoA reductase enzyme to effectively clear circulating LDL cholesterol. Additionally, other lipid-lowering agents such as ezetimibe, fibric acid derivatives, nicotinic acids, and omega-3 fatty acids are successfully utilized either as monotherapy or in combination regimens based on specific lipid goals.
Referanslar
Paul L. Canner, et al;Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin; J Am Coll Cardiol. 1986 Dec, 8 (6) 1245–1255.
Steven MHaffner ;Diabetes, hyperlipidemia, and coronary artery disease; The American Journal of Cardiology Volume 83, Issue 9, Supplement 2, 13 May 1999, Pages 17-21.
L.E Chambless, et al.,The association of corneal arcus with coronary heart disease and cardiovascular disease mortality in the Lipid Research Clinics Mortality Follow-up Study; American Journal of Public Health (AJPH)October 1990.
Grundy SM, et al.,Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines; Circulation, 2004 ;110:227-239.
Glass CK, Witztum JL., Atherosclerosis. The road ahead. Cell 2001;104:503-516.
Gary F. Lewis and Daniel J. Rader;New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport; Circulation Research. 2005;96:1221–1232.
Philip J. Barter,Stephen Nicholls,Kerry-Anne Rye,G.M. Anantharamaiah,Mohamad Navab and Alan M. FogelmanAntiinflammatory Properties of HDL; Circulation Research. 2004;95:764–772.
Sotirios Tsimikas, et al.,Lipoprotein(a) Reduction in Persons with Cardiovascular Disease; January16,2020N Engl J Med 2020; 382:244-255.
Anne Langsted, Pia R Kamstrup, Børge G Nordestgaard ;High lipoprotein(a) and high risk of mortality; European Heart Journal, Volume 40, Issue 33, 1 September 2019, Pages2760-2770.
Farah Aziz Khan , S.K.B.Patil , Amar Singh Thakur , Mohammad Fareed Khan , K. Murugan;Lipid Profile in Thyroid Dysfunction: A Study on Patients of Bastar; J Clin Anal Med 2014;5(1): 12-4.
Robert H.Knopp, BarbaraRetzlaffMPH, KeikoAikawa, Steven E.Kahn, Management of patients with diabetic hyperlipidemia; The American Journal of Cardiology
John DBrunzell ,Amir FAyyobi ;Dyslipidemia in the metabolic syndrome andtype 2 diabetes mellitus; The American Journal of Medicine Volume 115, Issue 8, Supplement 1, 8 December 2003, Pages 24-28.
Aleix Cases ElisabetColl ;Dyslipidemia and the progression of renal disease in chronic renal failure patients;Kidney InternationalVolume 68, Supplement 99, December 2005, Pages S87-S93.
Thomas Quaschning , VeraKrane , ThomasMetzger , ChristophWanner ;American Journal of Kidney DiseasesVolume 38, Issue 4, Supplement, October 2001, Pages S14-S19.
SS.Fojo, H.B. Brewer,Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II;Journal of medicine,volüme:231,issue;6;June 1992,669-677.
Anastazia A.KeiTheodosios D.FilippatosVasiliosTsimihodimosMoses S.Elisa ;A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease; Metabolism Volume 61, Issue 7, July 2012, Pages 906-921.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III; JAMA 2001 May 16;285(19):2486-97.
C.C. Shoulders, E.L. Jones, R.P. Naoumova; Genetics of familial combined hyperlipidemia and risk of coronary heart disease; Human Molecular Genetics, Volume 13, Issue suppl_1, 1 April 2004, Pages R149–R160.
John D. Brunzell, Hypertriglyceridemia; N Engl J Med 2007; 357:1009-1017.
Miho Karube, et al.,Lipoprotein glomerulopathy- like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 heterozygosity; Clinical and Experimental Nephrology volume 11, 2007,pages174–179
Daniel J. Rader, Jonathan Cohen, and Helen H. Hobbs, Monogenic hypercholesterolemia: new insights in pathogenesis and treatment; J Clin Innvest,2003;111(12):1795-1803.
Dick C. Chan;, et al.,Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia;Diabetes 2002;51(8):2377–2386.
Helen H. Hobbs, Daniel J. Rader ;ABC1: connecting yellow tonsils, neuropathy, and very low HDL;J Clin invest 1999;104:1015;1017.
Alan R. Tall; Role of ABCA1 in Cellular Cholesterol Efflux and Reverse Cholesterol Transport; Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:710–711.
William S. Yancy Jr , et al.,A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia; Annals of internal medicine,2004.
Antonio M. GottoJr;Cholesterol Management in Theory and Practice; Circulation. 1997;96:4424–4430.
Antonio M. Gotto Jr. Risks and benefits of continued aggressive statin therapy;Clin Cardiol 2003;26:III3-III1.
Scott M. Grundy ;The Issue of Statin SafetyWhere do We Stand?; Circulation. 2005;111:3016–3019.
Leslie J. Lipka;A First-in-Class, Novel Cholesterol Absorption Inhibitor;Cardiovascular Drug Reviews Volume21, Issue4.
Harold EBays,ET AL.,Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies; Clinical Therapeutics
Tsimihodimos, Vasilis, et al. ;Fenofibrate: Metabolic and Pleiotropic Effects; Current Vascular Pharmacology, Volume 3, Number 1, 2005, pp. 87-98(12)
L. A. CARLSON Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review; journal of internal medicine Volume258, Issue2 August 2005 Pages 94-114.
Lee Hooper, lecturer,Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review; BMJ 2006;332:752 Volume 23, Issue 8, August 2001, Pages 1209-1230.
